ERBB2 and breast cancer: Dual inhibition targeting both intracellular and extracellular domain of HER2 has also been tested in metastatic HER2 positive BC, as demonstrated by preclinical studies in HER2-positive cell lines, that shown a synergistic interaction between lapatinib and trastuzumab [47].